A Case Report on Primary Central Nervous System Lymphoma in Immunocompetent Individual.
ataxia
diffuse large b cell lymphoma
immunosuppression
pcnsl
primary cns lymphoma
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
accepted:
28
06
2021
entrez:
2
8
2021
pubmed:
3
8
2021
medline:
3
8
2021
Statut:
epublish
Résumé
Primary central nervous system lymphoma (PCNSL) is a rare form of CNS tumor. Immunosuppression is the most important risk factor of PCNSL, but few immunocompetent individuals are also affected. The most common clinical feature of PCNSL includes dizziness and ataxia. Our patient was a 71-year-old immunocompetent female who presented with progressive ataxia, imbalance, and dizziness for one year. A homogenous enhancing lesion was found in magnetic resonance imaging (MRI) of the head. One month later, on a follow-up MRI, a significant increase in the tumor size with surrounding edema was seen. The patient underwent craniotomy and resection of the mass. Subsequently, a diagnosis of diffuse large B cell lymphoma was made on pathology examination. Guideline-directed treatment options were discussed. This case highlights that the prognosis of patients with PCNSL highly depends on the factors such as age and physical status. Early diagnosis by accurate interpretation of imaging and management is crucial for better health outcomes.
Identifiants
pubmed: 34336481
doi: 10.7759/cureus.15990
pmc: PMC8318614
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e15990Informations de copyright
Copyright © 2021, Mandal et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet. 2009 Oct 31;374(9700):1512-20
pubmed: 19767089
Neuro Oncol. 2016 Oct 1;18(suppl_5):v1-v75
pubmed: 28475809
Dtsch Arztebl Int. 2018 Jun 22;115(25):419-426
pubmed: 29999484
J Clin Oncol. 2009 Jul 20;27(21):3503-9
pubmed: 19451444
Brain Tumor Pathol. 2001;18(2):161-5
pubmed: 11908874
J Natl Cancer Inst. 1996 May 15;88(10):675-9
pubmed: 8627644
J Int Med Res. 2020 Jul;48(7):300060520937839
pubmed: 32660288
Clin Radiol. 2016 Jun;71(6):602-9
pubmed: 27038652
Rinsho Shinkeigaku. 2013;53(10):803-8
pubmed: 24225563
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):379-385
pubmed: 27913504
Neuro Oncol. 2012 Dec;14(12):1481-4
pubmed: 22984018
Prog Neurol Surg. 2012;25:74-81
pubmed: 22236669
Blood. 2004 Mar 1;103(5):1869-75
pubmed: 14592832
J Clin Oncol. 2003 Jan 15;21(2):266-72
pubmed: 12525518
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Immunol Rev. 2012 May;247(1):172-83
pubmed: 22500840
Neuro Oncol. 2019 Feb 19;21(3):296-305
pubmed: 30418592
J Clin Oncol. 2005 Apr 1;23(10):2233-9
pubmed: 15800313